Delta-Fly Pharma Inc. has announced the schedule for the interim analysis of the Phase 3 study of DFP-10917 in relapsed/refractory acute myeloid leukemia (R/R AML) patients.
The interim analysis will be based on outcome measurements including complete remission rate, overall survival, and safety.
The first data processing is scheduled to be completed in mid-July 2023, followed by the second data processing at the end of November 2023.
The abstract of this phase 3 study will be submitted by the principal investigator at the annual meetings of ASH 2023 in San Diego and ASCO 2024 in Chicago.
Based on the results of this analysis, Delta-Fly Pharma Inc. is confident in their ability to deliver this drug to patients quickly with their partners.